CLINICAL ROLE -
Rx Product News Profile: A Closer Look at New FDA Actions: Novo Nordisk's Victoza
Novo Nordisk's Victoza (liraglutide), the first glucagon-like peptide-1 receptor agonist subcutaneous injection, received FDA approval for the treatment of type 2 diabetes mellitus.
Read More
Rx Product News Profile: A Closer Look at New FDA Actions: Bristol-Myers Squibb's and AstraZeneca's Onglyza
Onglyza (saxagliptin) comarketed by Bristol-Myers Squibb and AstraZeneca, is FDA-approved to improve glycemic control for the treatment of type 2 diabetes.